Ocular Therapeutix Inc (OCUL)

03:12 AM

Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test - MedCity News

03:12 AM

02:47 AM

Ocular Therapeutix Shares Fall After Eye Disease Treatment Shows Superiority in Phase 3 Trial at Week 36 - marketscreener.com

02:47 AM

02:34 AM

Ocular Therapeutix (OCUL) Shares Drop Amid Clinical Study Results - GuruFocus

02:34 AM

01:37 AM

Ocular: "Buy" As AXPAXLI Program For Wet-AMD Moves To Potential NDA Filing (NASDAQ:OCUL) - Seeking Alpha

01:37 AM

12:15 PM

Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk - Fierce Pharma

12:15 PM

11:48 AM

Ocular claims a win with eye drug data even as shares sink - BioPharma Dive

11:48 AM

11:31 AM

Ocular Therapeutix (OCUL) Stock Drops Following SOL-1 Trial Results - GuruFocus

11:31 AM

11:05 AM

Ocular Therapeutix releases positive topline results from SOL-1 - Ophthalmology Times

11:05 AM

10:56 AM

Ocular eyes superiority claim after Axpaxli success in wet AMD study, but shares fall - FirstWord Pharma

10:56 AM

10:32 AM

Ocular Therapeutix’s wet AMD treatment shows superiority over aflibercept - Investing.com Nigeria

10:32 AM

10:15 AM

Promising Biotech Ocular Gets Price Target Update After Groundbreaking Therapy News - TheStreet Pro

10:15 AM

10:03 AM

Ocular Therapeutix Shares Drop Following Axpaxli Trial Data Disappointment - Intellectia AI

10:03 AM

10:03 AM

Ocular Therapeutix Financial Results Disappoint Investors - StocksToTrade

10:03 AM

09:19 AM

Ocular Therapeutix Struggles After Missing Revenue Expectations - timothysykes.com

09:19 AM

09:09 AM

Ocular Therapeutix (OCUL) Drops 22% Despite Positive Trial Resul - GuruFocus

09:09 AM

08:56 AM

Ocular Therapeutix's AXPAXLI Meets Superiority Endpoint In Wet AMD Trial, But Stock Down - Nasdaq

08:56 AM

08:25 AM

Ocular drops after late-stage trial data for wet AMD therapy - Seeking Alpha

08:25 AM

08:06 AM

Ocular Therapeutix stock news: Why positive data led to a 25% drop - Investing.com Canada

08:06 AM

08:04 AM

Ocular Therapeutix (OCUL) Achieves Success in Phase 3 Trial for Wet AMD Treatment - GuruFocus

08:04 AM

07:22 AM

Ocular Therapeutix reports positive results from Sol-1 phase 3 superiority trial in wet AMD - marketscreener.com

07:22 AM

07:14 AM

Ocular Therapeutix stock tumbles after wet AMD trial results By Investing.com - Investing.com Canada

07:14 AM

07:12 AM

Ocular Therapeutix stock tumbles after wet AMD trial results - Investing.com UK

07:12 AM

07:08 AM

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial - TradingView

07:08 AM

07:05 AM

Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial - statnews.com

07:05 AM

07:03 AM

OCUL: AXPAXLI demonstrated statistically significant superiority to aflibercept in wet AMD at Week 52 - TradingView

07:03 AM

07:00 AM

Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD - GlobeNewswire

07:00 AM

05:34 AM

Ocular Therapeutix stock jumps in premarket as SOL-1 wet AMD data nears - Bez Kabli

05:34 AM

Feb 16, 2026

OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds - Stocktwits

Feb 16, 2026

Feb 16, 2026

Deep Track Capital, LP Reduces Stake in Ocular Therapeutix Inc - GuruFocus

Feb 16, 2026

Feb 16, 2026

Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes - Bitget

Feb 16, 2026

Feb 16, 2026

Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom - The Chronicle-Journal

Feb 16, 2026

Feb 16, 2026

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data - FinancialContent

Feb 16, 2026

Feb 16, 2026

Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - marketscreener.com

Feb 16, 2026

Feb 16, 2026

Ocular Therapeutix to Announce Topline Data from SOL-1 Phase 3 Trial for Wet AMD on February 17, 2026 - geneonline.com

Feb 16, 2026

Feb 14, 2026

Will Ocular Therapeutix Inc. benefit from geopolitical trendsTrade Risk Report & Long-Term Safe Investment Ideas - mfd.ru

Feb 14, 2026

Feb 13, 2026

Ocular Therapeutix to Host Webcast Presenting SOL-1 Data for AXPAXLI™ on February 17, 2026 - Quiver Quantitative

Feb 13, 2026

Feb 13, 2026

Ocular Therapeutix™ to Announce Topline Data for SOL-1 - GlobeNewswire

Feb 13, 2026

Feb 12, 2026

Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect (NASDAQ:OCUL) - Seeking Alpha

Feb 12, 2026

Feb 11, 2026

Ocular Therapeutix Equity Grants Balance Growth Plans And Dilution Concerns - Yahoo Finance

Feb 11, 2026

Feb 11, 2026

Why It's Time To Keep A Close Eye On OCUL - RTTNews

Feb 11, 2026

Feb 11, 2026

Ocular Therapeutix (OCUL) Stock Analysis: A Biotech Gem With 171% Upside Potential - DirectorsTalk Interviews

Feb 11, 2026

Feb 09, 2026

How Investors Are Reacting To Ocular Therapeutix (OCUL) Revenue Miss And Widening 2025 Net Loss - Sahm

Feb 09, 2026

Feb 08, 2026

Bearish Setup: Is Ocular Therapeutix Inc gaining market shareDay Trade & Daily Stock Trend Reports - baoquankhu1.vn

Feb 08, 2026

Feb 08, 2026

Ocular Therapeutix Faces Declining Sales and Profitability Amid Market Sentiment Shift - Markets Mojo

Feb 08, 2026

Feb 08, 2026

Aug Closing: Will Ocular Therapeutix Inc stock hit new highs in YEARMarket Sentiment Summary & Consistent Return Strategy Ideas - baoquankhu1.vn

Feb 08, 2026

Feb 07, 2026

Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL) - The Globe and Mail

Feb 07, 2026

Feb 07, 2026

Will Ocular Therapeutix Inc stock hit new highs in YEARWeekly Risk Summary & Safe Entry Point Identification - baoquankhu1.vn

Feb 07, 2026

Feb 07, 2026

Ocular Therapeutix (NASDAQ:OCUL) Raised to Hold at Wall Street Zen - MarketBeat

Feb 07, 2026

Feb 07, 2026

(OCUL) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Feb 07, 2026

Feb 06, 2026

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail

Feb 06, 2026

Feb 06, 2026

RBC Capital reiterates Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada

Feb 06, 2026

Feb 06, 2026

Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility - Sahm

Feb 06, 2026

Feb 06, 2026

Ocular Therapeutix Inc earnings beat by $0.03, revenue fell short of estimates - Investing.com South Africa

Feb 06, 2026

Feb 06, 2026

Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks - TipRanks

Feb 06, 2026

Feb 06, 2026

Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financials, Provides Business Highlights - VisionMonday.com

Feb 06, 2026

Feb 06, 2026

Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus

Feb 06, 2026

Feb 05, 2026

Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates - Finviz

Feb 05, 2026

Feb 05, 2026

Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says - marketscreener.com

Feb 05, 2026

Feb 05, 2026

Ocular Therapeutix (NASDAQ:OCUL) Shares Up 8.8% on Better-Than-Expected Earnings - MarketBeat

Feb 05, 2026

Feb 05, 2026

Ocular Q4 Revenue Declines; Phase 3 Wet AMD Trial Data Expected Later This Month - Nasdaq

Feb 05, 2026

Feb 05, 2026

Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Feb 05, 2026